statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Bitcoin

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Invesco QQQ Trust Series 1

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR - Get Free Report) have received a consensus rating of "Moderate Buy" from the twelve analysts that are presently covering the company, MarketBeat...

Brokerages Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) PT at $39.89

Clear Harbor Asset Management LLC bought a new position in Kymera Therapeutics, Inc. (NASDAQ:KYMR - Free Report) during the 4th quarter, according to the company in its most recent 13F filing with...

Clear Harbor Asset Management LLC Takes $255,000 Position in Kymera Therapeutics, Inc. (NASDAQ:KYMR)

Turnstone Biologics (NASDAQ:TSBX  Get Free Report) and Kymera Therapeutics (NASDAQ:KYMR  Get Free Report) are both medical companies, but which is the better stock? We will compare the...

Analyzing Kymera Therapeutics (NASDAQ:KYMR) & Turnstone Biologics (NASDAQ:TSBX)

Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) major shareholder Venture Fund X. L.P. Atlas sold 115,090 shares of the companys stock in a transaction on Wednesday, March...

Insider Selling: Kymera Therapeutics, Inc. (NASDAQ:KYMR) Major Shareholder Sells $4,860,250.70 in Stock

Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) major shareholder Venture Fund X. L.P. Atlas sold 42,302 shares of the stock in a transaction that occurred on Monday, March 11th. The...

Kymera Therapeutics, Inc. (NASDAQ:KYMR) Major Shareholder Venture Fund X. L.P. Atlas Sells 42,302 Shares

This is a signal that KYMR's price could be shifting from an uptrend to a downtrend. Traders may consider selling the stock or exploring put options...

Kymera Therapeutics (KYMR, $43.49) RSI Indicator left the overbought zone on March 08, 2024

Over the last three days, A.I.dvisor has detected that KYMR's AroonUp green line (see chart) is above 70, while the AroonDown red line is below 30. When the green line goes above 70 while the red...

Kymera Therapeutics (KYMR, $42.7) Aroon Indicator entered an Uptrend on March 07, 2024.

KT-621 (STAT6) and KT-294 (TYK2) have the potential to provide biologics-like activity with oral small molecule profiles KT-621 (STAT6) expected to start Phase 1 in second half of 2024 and KT-294...

Kymera Therapeutics Presents Preclinical Data for STAT6 and TYK2 First-In-Class, Oral Degrader Immunology Programs at the American Academy of Dermatology Annual Meeting

Shares of Kymera Therapeutics, Inc. (NASDAQ:KYMR  Get Free Report) have received an average rating of Moderate Buy from the twelve research firms that are covering the firm...

Analysts Set Kymera Therapeutics, Inc. (NASDAQ:KYMR) Price Target at $39.89

Kymera Therapeutics (KYMR, $41.86) Aroon Indicator entered an Uptrend on March 06, 2024.

Kymera Therapeutics, Inc. is a biopharmaceutical company, which engages in the discovery and development of small molecule therapeutics that degrade disease-causing proteins. The company was founded by Bruce Lee Booth and Nello Mainolfi in September 2015 and is headquartered in Watertown, MA.

Volume	81,474.00
52-Wk High	$45.31
52-Wk Low	$9.60

KYMR Kymera Therapeutics Inc

About

Feed

News

Sentiment

Earnings

Fundamentals